Body composition and physical fitness are major determinants of the growth hormone-insulin-like growth factor axis aberrations in adult Turner's syndrome, with important modulations by treatment with 17 beta-estradiol
- PMID: 9253336
- DOI: 10.1210/jcem.82.8.4127
Body composition and physical fitness are major determinants of the growth hormone-insulin-like growth factor axis aberrations in adult Turner's syndrome, with important modulations by treatment with 17 beta-estradiol
Abstract
The objectives of this study were to 1) study the GH-insulin-like growth factor (IGF) axis in adult untreated Turner's syndrome compared to that in age-matched controls; 2) examine the effects of sex hormone substitution on this axis, 3) study the effects of route of administration of 17 beta-estradiol on the measured variables, and 4) examine the effects of sex steroids on hepatic function in Turner patients. Twenty-seven patients with Turner's syndrome were evaluated before and during sex hormone replacement, and an age-matched control group (n = 24) was evaluated once. Main outcome variables were GH and other measures of the GH-IGF axis, body composition, maximal oxygen uptake, sex hormone-binding globulin, and hepatic enzymes and proteins. The integrated 24-h GH concentration (IC-GH; micrograms per L/24 h) was reduced in women with Turner's syndrome (T) compared to controls [C; mean +/- SD, 18.3 +/- 12.0 (T) vs. 37.2 +/- 29.7 (C); P = 0.007]. However, multiple regression revealed that fat-free mass (FFM) and maximal oxygen uptake were significant explanatory variables (joint r = 0.77; P < 0.0005), accounting for 60% of the variance in the 24-h IC-GH. This association was also present in controls. After adjustment for these two variables, any difference in GH concentration between Turner patients and controls disappeared. Serum IGF-I and IGF-II were identical in Turner patients and controls despite the difference in 24-h IC-GH. The level of GH-binding protein (GHBP; nanomoles per L) was higher in Turner women [1.87 +/- 0.72 (T) vs. 1.22 +/- 0.33 (C); P = 0.0005]; after adjustment for FFM, the difference in GHBP levels disappeared between Turner patients and controls. During sex hormone treatment a significant increase was seen in the 24-h IC-GH (P = 0.02), FFM (percentage of weight; P < 0.0005) and maximal oxygen uptake (milliliters of O2 per kg/min; P = 0.02). Serum IGF-I was unchanged, whereas serum IGF-II (micrograms per L) decreased significantly [Turner, basal (TB), vs. Turner, treatment (TT), 860 +/- 135 vs. 823 +/- 150; P = 0.04]. Alanine aminotransferase (units per L), gamma-glutamyl transferase (units per L), and alkaline phosphatase (units per L) were significantly elevated during the basal study period, and all decreased during treatment [alanine amino-transferase, 55 +/- 55 (TB) vs. 30 +/- 20 (TT; P = 0.006); gamma-glutamyl transferase, 92 +/- 98 (TB) vs. 43 +/- 65 (TT; P = 0.003); alkaline phosphatase, 211 +/- 113 (TB) vs. 175 +/- 54 (TT); P = 0.06]. The route of administration of 17 beta-estradiol did not affect its actions. In conclusion, we found the GH-IGF axis in Turner's syndrome to be normal, with body composition and physical fitness exerting the same modifying effects on this axis as seen in the normal population. Sex hormone replacement in Turner's syndrome is associated with normalizing effects on the GH-IGF axis, body composition, physical fitness, and hepatic function. The lowering of hepatic enzymes is a surprising and hitherto undiscovered action of sex steroids. Finally, the route of administration of 17 beta-estradiol is of minor importance in Turner's syndrome.
Similar articles
-
Glucose metabolism, lipid metabolism, and cardiovascular risk factors in adult Turner's syndrome. The impact of sex hormone replacement.Diabetes Care. 1998 Jul;21(7):1062-70. doi: 10.2337/diacare.21.7.1062. Diabetes Care. 1998. PMID: 9653596 Clinical Trial.
-
Serum growth hormone (GH)-binding protein and insulin-like growth factor-I levels in Turner's syndrome before and during treatment with recombinant human GH and ethinyl estradiol.J Clin Endocrinol Metab. 1992 Nov;75(5):1298-302. doi: 10.1210/jcem.75.5.1430092. J Clin Endocrinol Metab. 1992. PMID: 1430092
-
Plasma growth hormone-binding protein activity, insulin-like growth factor I, and its binding protein levels in patients with Turner's syndrome: effect of short- and long-term recombinant human growth hormone administration.Pediatr Res. 1995 Jan;37(1):106-11. doi: 10.1203/00006450-199501000-00020. Pediatr Res. 1995. PMID: 7535419
-
Metabolic effects of oestrogens: impact of the route of administration.Ann Endocrinol (Paris). 2003 Apr;64(2):170-7. Ann Endocrinol (Paris). 2003. PMID: 12773957 Review.
-
Turner's syndrome: a paediatric perspective.Horm Res. 2001;56 Suppl 1:38-43. doi: 10.1159/000048133. Horm Res. 2001. PMID: 11786684 Review.
Cited by
-
Interactive regulation of postmenopausal growth hormone insulin-like growth factor axis by estrogen and growth hormone-releasing peptide-2.Endocrine. 2001 Feb;14(1):45-62. doi: 10.1385/ENDO:14:1:045. Endocrine. 2001. PMID: 11322501 Review.
-
Clinical practice guidelines for the care of girls and women with Turner syndrome.Eur J Endocrinol. 2024 Jun 5;190(6):G53-G151. doi: 10.1093/ejendo/lvae050. Eur J Endocrinol. 2024. PMID: 38748847 Free PMC article.
-
Hepatic abnormalities in youth with Turner syndrome.Liver Int. 2022 Oct;42(10):2237-2246. doi: 10.1111/liv.15358. Epub 2022 Jul 16. Liver Int. 2022. PMID: 35785515 Free PMC article.
-
Sex hormone replacement in Turner syndrome.Endocrine. 2012 Apr;41(2):200-19. doi: 10.1007/s12020-011-9569-8. Epub 2011 Dec 7. Endocrine. 2012. PMID: 22147393 Review.
-
De novo aging-related NADPH diaphorase positive megaloneurites in the sacral spinal cord of aged dogs.Sci Rep. 2023 Dec 14;13(1):22193. doi: 10.1038/s41598-023-49594-0. Sci Rep. 2023. PMID: 38092874 Free PMC article.